Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 304

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 304
---
-approved and that are not prohibited by regulatory or other professional requirements. This policy provides for pre-approval of certain types of services through the use of an annual budget approved by the Audit Committee for these types of services. The Audit Committee reviews on an annual basis the services provided by the statutory auditors. See Note E. to our consolidate d financial statements included at Item 18. of this annual report. Item 16D. Exemptions from the Listing Standards for Audit Committees N/A

| SANOFIFORM 20-F2024 | 181 |

| PART II                                                                          |
| ITEM 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers |

Item 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers In 2024 , Sanofi made the following purchases of its ordinary shares.

| Period(a)    | (A) Total Number ofShares Purchased | (B) Average Price Paidper Share | -C) Total Numberof Shares Purchasedas Part of PubliclyAnnounced Plansor Programs(b | -D) ApproximateValue of Sharesthat May Yet BePurchased Under thePlans or Programs(c |
| January 2024 |                           3,215,460 |                           93.57 |                                                                          3,215,460 |                                                                              18,382 |
| Total        |                           3,215,460 |                                 |                                                                                    |                                                                                     |

(a) On February 2, 2025, Sanofi and L'Oréal entered into a share purchase agreement pursuant to which Sanofi repurchased 29,556,650 shares from L’Oréal, a significant shareholder, at €101.50 per share, for a total amount of approximately €3 billion. After the transaction, L’Oréal holds 7.2% of Sanofi’s share capital and 13.1% of its actual voting rights (excluding treasury shares). The transaction closed on February 5, 2025. Sanofi will cancel the shares acquired from L'Oréal at the latest on April 29, 2025. In addition, on February 6, 2025 Sanofi mandated an investment services provider to carry out further share repurchases up to a maximum of €2 billion, between February 7, 2025 and December 31, 2025 at the latest. . For more information, see "Item 8. Financial Information - B. Significant Changes". (b) Sanofi was authorized